Treatment of acute rhinitis with a nasal spray containing tramazoline and essential oils: a multicenter, uncontrolled, observational trial. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Katona, Gábor; Sultész, Mónika; Farkas, Zsolt; Gyimesi, Andrea; Hirschberg, Andor; Huszka, János; Radvánszky, Ferenc; Simon, Ákos; Fülöp, Gabriella; Láng, Júlia; Ablonczy, Mária; Nirnberger, Günther; Holm, Claudia
• Is Part Of: Clinical and translational allergy. Volume 5:Issue 1(2015)
• Page Start: 1
• Page End: 8
• Publication Date: 2015-12
• Subjects: Allergy -- Periodicals; Immunology -- Periodicals; Allergy and Immunology -- Periodicals; Hypersensitivity -- Periodicals; Immune System Phenomena -- Periodicals; 616.97005
• DOI: 10.1186/s13601-015-0084-5
• Languages: English
• ISSNs: 2045-7022

Abstract

Abstract Background In this observational trial, data were collected on the effectiveness and tolerability/safety of a nasal spray containing tramazoline and essential oils (trade name Rhinospray® Plus) used for symptomatic treatment of acute rhinitis due to common cold. Methods The trial was performed in 300 children, adolescents and adults, who were to be treated with Rhinospray® Plus for up to 4 times per day for up to 10 days. Primary endpoints were the change from baseline to final visit in the mean of three single symptom scores (blocked nose, sneezing, and runny nose) and the mean improvement in two quality-of-life parameters (ability to perform normal daytime activities and quality of sleep). Results A total of 108 children, 30 adolescents and 162 adults were treated with Rhinospray® Plus. No patient discontinued prematurely. There was a mean reduction of 2.0 ± 0.6 (standard deviation) in nasal symptom scores from baseline to final visit; 297 of 300 of patients (99.0 %) reported an improvement. The mean value for improvement in quality-of-life parameters was 1.3 ± 0.5. Improvement in daytime activities was reported by all 300 patients (100.0 %) and in quality of sleep by 292 patients (97.4 %). Effectiveness and tolerability were rated as 'very good' or 'good' by 95.4 % and 97.4 % of patients, respectively; the investigators rated effectiveness and tolerability as 'very good' or 'good' for 97.4 % and 100.0 % of patients, respectively. No adverse events were reported. Conclusions Community-based patients reported a relief in acute rhinitis symptoms and improvement in quality of life as a result of treatment with Rhinospray® Plus. Treatment was well-tolerated.